LRRK2 mutation in familial Parkinson’s disease in a Taiwanese population: clinical, PET, and functional studies (original) (raw)

References

  1. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, Müller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK, Gasser T (2004) Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron 44:601–607
    Article PubMed CAS Google Scholar
  2. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson’ s disease. Neuron 44:595–600
    Article PubMed Google Scholar
  3. Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, Tsuji S, Obata F (2005) An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57:918–921
    Article PubMed CAS Google Scholar
  4. Lu CS, Simons EJ, Wu-Chou YH, Fonzo AD, Chang HC, Chen RS, Weng YH, Rohé CF, Breedveld GJ, Hattori N, Gasser T, Oostra BA, Bonifati V (2005) The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson’s disease. Parkinsonism Relat Disord 11:521–522
    Article PubMed Google Scholar
  5. Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, Jamora RD, Puvan K, Puong KY, Zhao Y, Pavanni R, Wong MC, Yih Y, Skipper L, Liu JJ (2005) The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson’s disease patients. Neurosci Lett 384:327–329
    Article PubMed CAS Google Scholar
  6. Tomiyama H, Li Y, Funayama M, Hasegawa K, Yoshino H, Kubo S, Sato K, Hattori T, Lu CS, Inzelberg R, Djaldetti R, Melamed E, Amouri R, Gouider-Khouja N, Hentati F, Hatano Y, Wang M, Imamichi Y, Mizoguchi K, Miyajima H, Obata F, Toda T, Farrer MJ, Mizuno Y, Hattori N (2006) Clinicogenetic study of mutations in LRRK2 exon 41 in Parkinson’s disease patients from 18 countries. Mov Disord 21:1102–1108
    Article PubMed Google Scholar
  7. Fung HC, Chen CM, Hardy J, Hernandez D, Singleton A, Wu YR (2006) Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson’s disease. Mov Disord 21:880–881
    Article PubMed Google Scholar
  8. Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, Hulihan MM, Cobb SA, Wu RM, Lu CS, Lahoz C, Wszolek ZK, Farrer MJ (2005) Lrrk2 pathogenic substitutions in Parkinson’s disease. Neurogenetics 6:171–177
    Article PubMed CAS Google Scholar
  9. Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohé CF, Chang HC, Chen RS, Weng YH, Vanacore N, Breedveld GJ, Oostra BA, Bonifati V (2006) A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson’s disease risk in Taiwan. Neurogenetics 7:133–138
    Article PubMed CAS Google Scholar
  10. Farrer MJ, Stone JT, Lin CH, Dächsel JC, Hulihan MM, Haugarvoll K, Ross OA, Wu RM (2007) Lrrk2 G2385R is an ancestral risk factor for Parkinson’s disease in Asia. Parkinsonism Relat Disord 13:89–92
    Article PubMed Google Scholar
  11. Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR (2006) A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 6:47
    Google Scholar
  12. Funayama M, Li Y, Tomiyama H, Yoshino H, Imamichi Y, Yamamoto M, Murata M, Toda T, Mizuno Y, Hattori N (2007) Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 18:273–275
    Article PubMed CAS Google Scholar
  13. Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, Fook-Chong S, Tang S, Chua E, Yuen Y, Tan L, Pavanni R, Wong MC, Kolatkar P, Lu CS, Bonifati V, Liu JJ (2007) The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence. Hum Genet 120:857–863
    Article PubMed CAS Google Scholar
  14. Cao L, Zhang T, Xiao Q, Wang Y, Bai L, Lu GQ, Ma JF, Zhang J, Ding JQ, Chen SD (2007) The prevalence of LRRK2 Gly2385Arg variant in Chinese Han population with Parkinson’s disease. Mov Disord 15:2439–2443
    Article Google Scholar
  15. Ana XK, Penga R, Lib T, Burgundera JM, Wua Y, Chena WJ, Zhanga JH, Wang YC, Xua YM, Gou YR, Yuan GG, Zhang ZJ (2008) LRRK2 Gly2385Arg variant is a risk factor of Parkinson’s disease among Han-Chinese from mainland China. Eur J Neurol. Jan 14 [Epub ahead of print]
  16. Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohé CF, Riboldazzi G, Antonini A, Albani G, Mauro A, Marconi R, Abbruzzese G, Lopiano L, Fincati E, Guidi M, Marini P, Stocchi F, Onofrj M, Toni V, Tinazzi M, Fabbrini G, Lamberti P, Vanacore N, Meco G, Leitner P, Uitti RJ, Wszolek ZK, Gasser T, Simons EJ, Breedveld GJ, Goldwurm S, Pezzoli G, Sampaio C, Barbosa E, Martignoni E, Oostra BA, Bonifati V, Italian Parkinson’s Genetics Network (2006) Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson’s disease. Eur J Hum Genet 14:322–331
    Article PubMed CAS Google Scholar
  17. Fahn S, Elton RI, Members of the UPDRS Development Committee UPsDRS (1987) Recent developments in Parkinson’s Disease. In: Fahn S, Marsden CD, Goldstein M, Calne CD (eds) The unified Parkinson’s disease rating scale, vol II. McMillan Healthcare Information, Florham Park, NJ, pp 153–163
    Google Scholar
  18. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
    Article PubMed CAS Google Scholar
  19. Doty RL, Shaman P, Dann M (1984) Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 32:489–502
    Article PubMed CAS Google Scholar
  20. Wu RM, Shan DE, Sun CM, Liu RS, Hwu WL, Tai CH, Hussey J, West A, Gwinn-Hardy K, Hardy J, Chen J, Farrer M, Lincoln S (2002) Clinical, 18F-dopa PET, and genetic analysis of an ethnic Chinese kindred with early-onset parkinsonism and Parkin gene mutations. Mov Disord 17:670–675
    Article PubMed Google Scholar
  21. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39
    Article PubMed CAS Google Scholar
  22. Neitzel H (1986) A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet 73:320–326
    Article PubMed CAS Google Scholar
  23. Qiu JH, Asai A, Chi S, Saito N, Hamada H, Kirino T (2000) Proteasome inhibitors induce cytochrome c-caspase-3-like protease-mediated apoptosis in cultured cortical neurons. J Neurosci 20:259–265
    PubMed CAS Google Scholar
  24. Mata IF, Taylor JP, Kachergus J, Hulihan M, Huerta C, Lahoz C, Blazquez M, Guisasola LM, Salvador C, Ribacoba R, Martinez C, Farrer M, Alvarez V (2005) LRRK2 R1441G in Spanish patients with Parkinson’s disease. Neurosci Lett 382:309–311
    Article PubMed CAS Google Scholar
  25. Zabetian CP, Samii A, Mosley AD, Roberts JW, Leis BC, Yearout D, Raskind WH, Griffith A (2005) A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations. Neurology 65:741–744
    Article PubMed CAS Google Scholar
  26. Spanaki C, Latsoudis H, Plaitakis A (2006) LRRK2 mutations on Crete: R1441H associated with PD evolving to PSP. Neurology 67:1518–1519
    Article PubMed Google Scholar
  27. Huang Y, Halliday GM, Vandebona H, Mellick GD, Mastaglia F, Stevens J, Kwok J, Garlepp M, Silburn PA, Horne MK, Kotschet K, Venn A, Rowe DB, Rubio JP, Sue CM (2007) Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson’s Disease. Mov Disord 22:982–989
    Article PubMed Google Scholar
  28. Ferreira JJ, Guedes LC, Rosa MM, Coelho M, van Doeselaar M, Schweiger D, Di Fonzo A, Oostra BA, Sampaio C, Bonifati V (2007) High prevalence of LRRK2 mutations in familial and sporadic Parkinson’s disease in Portugal. Mov Disord 22:1194–1201
    Article PubMed Google Scholar
  29. Ross OA, Toft M, Whittle AJ, Johnson JL, Papapetropoulos S, Mash DC, Litvan I, Gordon MF, Wszolek ZK, Farrer MJ, Dickson DW (2006) Lrrk2 and Lewy body disease. Ann Neurol 59:388–93
    Article PubMed CAS Google Scholar
  30. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
    Article PubMed Google Scholar
  31. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102:16842–16847
    Article PubMed CAS Google Scholar
  32. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, van der Brug MP, Beilina A, Blackinton J, Thomas KJ, Ahmad R, Miller DW, Kesavapany S, Singleton A, Lees A, Harvey RJ, Harvey K, Cookson MR (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23:329–341
    Article PubMed CAS Google Scholar
  33. Tan EK, Fook-Chong S, Yi Z (2007) Comparing LRRK2 Gly2385Arg carriers with noncarriers. Mov Disord 22:749–750
    Article PubMed Google Scholar
  34. Lee MJ, Mata IF, Lin CH, Tzen KY, Lincoln SJ, Bounds R, Lockhart PJ, Hulihan MM, Farrer MJ, Wu RM (2008) Genotype–phenotype correlates in Taiwanese patients with early-onset recessive parkinsonism. Mov Disord (in press)

Download references